论文部分内容阅读
目的分析胸腺肽α1在小儿呼吸机相关肺炎(VAP)治疗中的临床疗效。方法选取2012年7月—2014年7月巴中市中医院儿科重症监护病房(PICU)收治的VAP患儿60例,根据随机数字表法分为观察组和对照组,各30例。两组患儿均给予常规治疗,观察组患儿在此基础上加用胸腺肽α1。比较两组患儿临床疗效、机械通气时间和住院时间、免疫学指标及不良反应。结果观察组患儿临床疗效优于对照组(u=2.13,P<0.05)。观察组患儿机械通气时间、住院时间均短于对照组(P<0.05)。两组患儿治疗前CD+4、CD+8、NK细胞分数及CD+4/CD+8比值比较,差异均无统计学意义(P>0.05);观察组患儿治疗后CD+4、NK细胞分数及CD+4/CD+8比值均高于对照组(P<0.05)。两组患儿均未见明显不良反应。结论胸腺肽α1治疗小儿VAP疗效显著,安全可靠。
Objective To analyze the clinical efficacy of thymosin α1 in the treatment of ventilator-associated pneumonia (VAP) in children. Methods From July 2012 to July 2014, 60 children with VAP admitted to pediatric intensive care unit (PICU) of Bazhong Hospital of Traditional Chinese Medicine were divided into observation group and control group according to the random number table method, 30 cases in each group. Two groups of children were given conventional treatment, the observation group of children on the basis of the addition of thymosin α1. The clinical efficacy, mechanical ventilation time, hospital stay, immunological parameters and adverse reactions in both groups were compared. Results The clinical efficacy of observation group was better than that of control group (u = 2.13, P <0.05). The observation group patients with mechanical ventilation time, hospitalization were shorter than the control group (P <0.05). There was no significant difference in the scores of CD + 4, CD + 8, NK cells and CD + 4 / CD + 8 between the two groups before treatment (P> 0.05) NK cell fraction and CD + 4 / CD + 8 ratio were higher than the control group (P <0.05). No significant adverse reactions in both groups of children. Conclusions Thymosin α1 is effective in treating VAP in children and is safe and reliable.